Utrecht (The Netherlands), Boston (United States) – Ablative Solutions, Inc. (Kalamazoo, Michigan), a medtech company pioneering new approaches for the treatment of hypertension, today announced the first close of its USD 77 million Series D funding round. The round was led by Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor. Existing investors, including Michigan Accelerator Fund, Novus Biotechnology and other individual investors rounded out the financing.

Funds from the round will be used to complete clinical trials in support of U.S. and European regulatory submissions for the company’s minimally invasive renal denervation technology designed to help reduce blood pressure for people with uncontrolled hypertension.

Ablative Solutions’ alcohol-mediated renal denervation procedure is performed using the investigational Peregrine System Kit™, which is engineered to target nerves known to influence the body’s regulation of blood pressure. The Peregrine Kit delivers dehydrated alcohol in small doses directly to the space outside of the renal artery to block the overactive signaling of the sympathetic nerves. This targeted treatment is designed to be performed in a rapid, straightforward procedure with minimal pain or discomfort for the patient.

Drug therapy and lifestyle changes are the most common treatments for hypertension. Medication non-adherence remains a serious and underappreciated limitation of drug therapy. More than half of those treated do not achieve their target blood pressure, highlighting the need for improved therapeutic options.

About the Peregrine System Infusion Catheter
The Peregrine System Infusion Catheter has 510(k) clearance for the infusion of diagnostic and therapeutic agents into the perivascular area of the peripheral vasculature. The Peregrine System Infusion Catheter is CE marked for the infusion of a neurolytic agent to achieve a reduction in systemic blood pressure in hypertensive patients.

About Ablative Solutions
Ablative Solutions, Inc., based in Kalamazoo, Mich., and San Jose, Calif., was founded in 2011 with a vision to address the unmet need of hypertension. Ablative Solutions’ approach targets the overactive sympathetic nervous system, which may play a role in hypertension, heart failure, kidney disease, metabolic syndrome and sleep apnea. The Peregrine System Infusion Catheter provides physicians with a way to infuse diagnostic and therapeutic agents into the area surrounding the renal artery, where sympathetic nerves are located. The Peregrine System Kit is currently being investigated as a treatment for hypertension in conjunction with antihypertensive medications. For more information visit ablativesolutions.com.

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing EUR 1 billion across two business lines: a venture & growth capital fund and a private equity fund. Gilde Healthcare’s venture & growth capital fund invests in therapeutics, medtech and digital health. The portfolio companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable lower mid-market European healthcare services companies with a focus on the Benelux and DACH region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. The venture & growth fund is currently investing out of Gilde Healthcare IV which is financed, in part, by the European Recovery Program-European Investment Fund Facility. For more information, visit the company’s website at gildehealthcare.com.

Equity Round led by Bain Capital Life Sciences
Redwood City, CA – January 3, 2019 – Gynesonics, a women’s healthcare company and the
developer of the Sonata System and other advanced, incision-free solutions for the treatment of
uterine conditions, today announced that it has completed a $75 million equity financing. The
financing was led by Bain Capital Life Sciences and included all of the Company’s existing
investors, including Abingworth, Advanced Technology Ventures (ATV), Endeavour Vision,
HealthCrest, InterWest Partners, HBM Partners, Correlation Ventures and Hercules Technology
Growth Capital.

The Sonata (Sonography-Guided Transcervical Fibroid Ablation) System is intended for the
diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids,
including those associated with heavy menstrual bleeding. The system combines a novel
integrated technology — the first and only intrauterine ultrasound system — with a proprietary
radiofrequency ablation device, providing a transcervical, incision-free, uterus-preserving
treatment for uterine fibroids. This breakthrough technology platform provides access to a wide
range of fibroid types, many of which cannot be treated with current operative hysteroscopy
methods.

Concurrent with the financing, Jeffrey Schwartz, a Managing Director of Bain Capital Life
Sciences, will join the Gynesonics Board of Directors.
“We are impressed by the quality and promise of the Sonata System and the caliber of the
Gynesonics team,” said Schwartz. “We believe there is a strong clinical need for an incision-free
option for women who are suffering from symptomatic fibroids. I look forward to joining the
board and working closely with the team on this important platform technology as well as other
advances in the company pipeline.”
“The Sonata System is poised to make a significant impact in the way women are treated for this
incapacitating disease,” stated Ken Haas, Partner, Abingworth. “As a founding investor in
Gynesonics, we are excited to help pioneer this new approach and to continue working with the
management team on its path toward successful commercialization.”
“We are confident that Gynesonics is well-positioned to meet the needs of women who suffer
from this debilitating disease. The robust and impressive clinical data will enable the Sonata
System to make a significant impact in the multi-billion worldwide market for the treatment of
uterine fibroids,” stated existing investor and Board Member, Mike Carusi, General Partner,
Advanced Technology Ventures.

Gynesonics will use the proceeds from the financing to launch the global commercialization of
the Sonata System. The Sonata System has a CE Mark for marketing in the European Union and
received U.S. Food and Drug Administration (FDA) 510(k) clearance in August.
The company will also use proceeds to further develop the Sonata technology platform, and for
additional clinical research initiatives to support reimbursement and market development
objectives.

“On behalf of all of the stakeholders in Gynesonics, I welcome Bain Capital as a new investor
and Jeff as a new member of our board,” said Christopher M. Owens, President and CEO of
Gynesonics. “Gynesonics has developed a breakthrough treatment option for symptomatic
uterine fibroids that is designed to preserve the uterus. We are proud to offer physicians and the
women under their care a new treatment choice for this disease. This financing will provide the
capital to successfully commercialize the Sonata System and continue the clinical research
essential to our market development objectives.”

According to medical literature, about 70-80 percent of women in the U.S. will develop uterine
fibroids by age 50 with a significant proportion of the fibroids causing symptoms. In addition,
according to the New England Journal of Medicine, approximately 200,000 hysterectomies are
performed in the U.S. each year because of uterine fibroids.
With an estimated volume of more than 1 million annual global fibroid procedures, Gynesonics
projects a $3 billion-$4 billion global market opportunity for its Sonata System, including a
market opportunity of more than $1 billion in the U.S. alone.

About Bain Capital Life Sciences
Bain Capital Life Sciences pursues investments in biopharmaceutical, specialty pharmaceutical,
medical device, diagnostics and enabling life science technology companies globally. The team
focuses on companies that both drive medical innovation across the value chain and enable that
innovation to improve the lives of patients with unmet medical needs. Through its private equity
business, the firm has significant experience working with companies focused on women’s
health issues including through its prior ownership of Warner Chilcott.

About Sonata System
The Sonata System, the next generation of Gynesonics’ technology platform (the previous
generation referred to as VizAblate), uses radiofrequency energy to ablate fibroids under
intrauterine sonography guidance. The Sonata System, including the SMART Guide, enables the
operator to target fibroids and optimize ablations within them. Sonata System’s design provides a
straightforward, transcervical access for a uterus preserving, incision-free fibroid treatment. This
intrauterine approach is designed to treat a wide range of fibroid types while avoiding the
peritoneal cavity.

About Gynesonics
Gynesonics is a women’s healthcare company focused on advancing women’s health, by
developing minimally invasive, transcervical, uterus-preserving, incision-free technologies for
diagnostic and therapeutic applications. Gynesonics has developed the Sonata System for
diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. The
Sonata System is CE marked. Sonata is approved for sale in the European Union and the United
States. Gynesonics is a privately held company with headquarters in Redwood City, CA. For
more information, go to www.gynesonics.com.

CONTACT:
Chris Owens, Gynesonics President and CEO
+1.650.216.3860
www.gynesonics.com